These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35726496)
21. miR-155 in the progression of lung fibrosis in systemic sclerosis. Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409 [TBL] [Abstract][Full Text] [Related]
22. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053 [TBL] [Abstract][Full Text] [Related]
23. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Lee R; Reese C; Bonner M; Tourkina E; Hajdu Z; Riemer EC; Silver RM; Visconti RP; Hoffman S Am J Physiol Lung Cell Mol Physiol; 2014 Apr; 306(8):L736-48. PubMed ID: 24583879 [TBL] [Abstract][Full Text] [Related]
24. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease. Birnhuber A; Jandl K; Biasin V; Fließer E; Valzano F; Marsh LM; Krolczik C; Olschewski A; Wilhelm J; Toller W; Heinemann A; Olschewski H; Wygrecka M; Kwapiszewska G Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35332068 [TBL] [Abstract][Full Text] [Related]
25. Dysregulation of TNF-induced protein 3 and CCAAT/enhancer-binding protein β in alveolar macrophages: Implications for systemic sclerosis-associated interstitial lung disease. Hua X; Hongbing R; Juan X; Jizan L; Beibei Y Int J Rheum Dis; 2024 May; 27(5):e15174. PubMed ID: 38720423 [TBL] [Abstract][Full Text] [Related]
26. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease. Papazoglou A; Huang M; Bulik M; Lafyatis A; Tabib T; Morse C; Sembrat J; Rojas M; Valenzi E; Lafyatis R Arthritis Rheumatol; 2022 Dec; 74(12):2003-2014. PubMed ID: 35849803 [TBL] [Abstract][Full Text] [Related]
27. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? Jimenez SA; Piera-Velazquez S Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760 [TBL] [Abstract][Full Text] [Related]
28. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Wollin L; Trinh-Minh T; Zhang Y; Distler JHW Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452 [TBL] [Abstract][Full Text] [Related]
29. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328 [TBL] [Abstract][Full Text] [Related]
31. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427 [TBL] [Abstract][Full Text] [Related]
32. Deregulated PSGL-1 Expression in B Cells and Dendritic Cells May Be Implicated in Human Systemic Sclerosis Development. Silván J; González-Tajuelo R; Vicente-Rabaneda E; Pérez-Frías A; Espartero-Santos M; Muñoz-Callejas A; García-Lorenzo E; Gamallo C; Castañeda S; Urzainqui A J Invest Dermatol; 2018 Oct; 138(10):2123-2132. PubMed ID: 29689251 [TBL] [Abstract][Full Text] [Related]
33. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320 [TBL] [Abstract][Full Text] [Related]
34. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. Khanna SA; Nance JW; Suliman SA Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699 [TBL] [Abstract][Full Text] [Related]